Vollagen® benefits in GLP-1 users: the consumer study results

GLP-1 receptor agonist therapies have changed what a significant group of consumers wants from a supplement, and they have done it quickly. The weight loss is substantial and often rapid. What follows it is becoming just as widely discussed: skin that has lost its firmness, faces that look hollowed, and hair that sheds.

This is no longer anecdotal. A 2026 patient-reported study found a clear relationship between the amount of weight lost and the visible changes that came with it. Among people who lost more than 20% of their body weight, 72% reported skin sagging, 52% reported hair loss and 50% reported a loss of facial volume. Below 10% weight loss those figures drop sharply, to 15%, 17% and 13% respectively. The pattern is consistent: the more weight comes off, and the faster, the more visible the consequences.

Hair is the area where the evidence has moved fastest. A 2026 meta-analysis covering 4,114 GLP-1 users reported an overall hair-loss event rate of 3.9%, and a 3.25-fold higher risk compared with placebo. Regulatory trial data for semaglutide and tirzepatide also record hair loss, particularly in women. Rapid weight reduction is a plausible contributor through telogen effluvium, and reduced food intake can compound the problem where protein or micronutrient intake becomes inadequate.

For anyone building nutricosmetic products, that is a formulation brief sitting in plain sight. The question is what to put behind it.

Why we ran the study

Vollagen® has a long-standing evidence base in general skin perception. What it did not have was data in the specific population now asking these questions.

Rather than infer from that general collagen data and hope the argument held, we commissioned Ayton Global Research to test Vollagen® VGN4 in adults actually taking GLP-1 injections or medication. Ayton specialises in substantiating perception claims and works under ISO 9001 alongside ESOMAR, MRS and MRC principles, which matters when the output is intended to support marketing claims.

How the study was designed

The study ran as a 60-day single-placement in-home user study in the United Kingdom, with performance dates from 18 June to 12 August 2026. Fifty-eight volunteers took part and 51 were included in the result data. Participants took 1,000 mg of Vollagen® VGN4 daily, as two capsules with a meal, and completed questionnaires at four weeks and at eight weeks.

Perception statements used a nine-point response scale, with scores of six to nine categorised as satisfied. Before the study began, a 66% satisfaction pass mark was set for claim substantiation. Every figure below cleared a threshold that was fixed in advance rather than chosen afterwards to suit the results.

What came back

After four weeks, hydration and radiance were the strongest early perceptions. 80.39% of respondents agreed that their skin felt hydrated, and the same proportion agreed that it looked hydrated. Radiance reached 74.51%. Suppleness and firmness both reached 72.55%.

By eight weeks the picture held. 76.47% still reported hydrated-feeling skin, 74.51% hydrated-looking skin and 72.55% radiant-looking skin. Suppleness sat at 68.63% and firmness at 66.67%, both still at or above the pass mark.

The hair results are the ones worth pausing on. At eight weeks, 66.67% of participants reported healthier-feeling hair and 66.67% reported shinier-looking hair. Hair improvements typically take several weeks before anything registers and months before they mean much, so a two-thirds response inside eight weeks is a genuinely useful signal in a category where shedding is becoming the headline concern.

One further result is easy to overlook and commercially relevant: 90.20% of respondents said the supplement fitted well into their daily routine, the highest satisfaction score recorded at week four. Adherence is not a glamorous metric, but a product nobody keeps taking delivers nothing.

What this does and does not show

It is worth being precise about what was measured. This is a consumer-perception study, not a clinical trial. It records what people reported about their own skin and hair, assessed against a predefined threshold, and it should be described that way.

The panel was entirely female, with the largest age group being 40 to 49 years. That reflects the current GLP-1 nutricosmetic consumer closely, but it is a characteristic of the study worth stating.

There is also a distinction that no supplement should blur. A separate radiographic study of 20 GLP-1 users reported a median 9% reduction in total midfacial volume after an average 11.0 kg of weight loss, at roughly 7% midfacial volume loss per 10 kg. A nutritional supplement cannot replace lost facial fat. Supporting the quality of the overlying skin is a different objective, and a legitimate one, but the two should not be presented as the same thing.

What it opens up

Vollagen® is a plant-source complex of amino acids, designed around the amino-acid profile of human collagen. That positioning does something animal-derived collagen cannot: it puts the collagen conversation into vegan, vegetarian and cruelty-free formats, at 1,000 mg a day in two capsules rather than a large gram-dose powder.

Set against a category where almost every collagen product is animal-derived, and a consumer group that is both growing quickly and highly motivated, that combination is unusual. Vollagen® now has direct consumer-perception data in exactly that user group, with a claim platform built on results that cleared a threshold set before the study started.

Read the full study

The complete report covers the methodology, the four and eight week results in full, the claims jurisdiction position under ASA rules, and a recommended headline claim platform you can build products and marketing against.

Download the full study

If you are working on a nutricosmetic concept for this market, or want to talk through where Vollagen® fits in a formulation, email info@protecnutra.com